242 related articles for article (PubMed ID: 22156223)
1. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.
Inoyama D; Chen Y; Huang X; Beamer LJ; Kong AN; Hu L
J Biomol Screen; 2012 Apr; 17(4):435-47. PubMed ID: 22156223
[TBL] [Abstract][Full Text] [Related]
2. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
3. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
Schaap M; Hancock R; Wilderspin A; Wells G
Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
[TBL] [Abstract][Full Text] [Related]
4. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction.
Hancock R; Bertrand HC; Tsujita T; Naz S; El-Bakry A; Laoruchupong J; Hayes JD; Wells G
Free Radic Biol Med; 2012 Jan; 52(2):444-51. PubMed ID: 22107959
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance.
Chen Y; Inoyama D; Kong AN; Beamer LJ; Hu L
Chem Biol Drug Des; 2011 Dec; 78(6):1014-21. PubMed ID: 21920027
[TBL] [Abstract][Full Text] [Related]
6. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.
Wells G
Biochem Soc Trans; 2015 Aug; 43(4):674-9. PubMed ID: 26551711
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a Steady-State FRET Assay in Cancer Chemoprevention.
Schaap MC; Guimarães AM; Wilderspin AF; Wells G
Methods Mol Biol; 2016; 1379():165-79. PubMed ID: 26608299
[TBL] [Abstract][Full Text] [Related]
8. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.
Jain A; Lamark T; Sjøttem E; Larsen KB; Awuh JA; Øvervatn A; McMahon M; Hayes JD; Johansen T
J Biol Chem; 2010 Jul; 285(29):22576-91. PubMed ID: 20452972
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
[TBL] [Abstract][Full Text] [Related]
10. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
12. Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.
Zhuang C; Miao Z; Sheng C; Zhang W
Curr Med Chem; 2014; 21(16):1861-70. PubMed ID: 24533814
[TBL] [Abstract][Full Text] [Related]
13. Development of an enzyme-linked immunosorbent assay for Keap1-Nrf2 interaction inhibitors identification.
Wang Y; Xiao CY; Lin HQ; Hu JS; Ip TM; Chi-Cheong Wan D
Redox Biol; 2020 Jul; 34():101573. PubMed ID: 32422542
[TBL] [Abstract][Full Text] [Related]
14. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
[TBL] [Abstract][Full Text] [Related]
15. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the negative regulator of Nrf2, Keap1: a historical overview.
Itoh K; Mimura J; Yamamoto M
Antioxid Redox Signal; 2010 Dec; 13(11):1665-78. PubMed ID: 20446768
[TBL] [Abstract][Full Text] [Related]
19. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
